Health
Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial – The Lancet
This first-in-human trial shows that a subunit vaccine comprising mammalian cell culture-derived,MF59-adjuvanted, molecular clamp-stabilised recombinant spike protein…
We use cookies to help provide and enhance our service and tailor content and ads. To update your cookie settings, please visit the Cookie Preference Center for this site.Copyright © 2021 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.
Privacy Policy Terms and Conditions
-
Noosa News22 hours agoRallies under way as nationwide support for Palestine surges
-
General21 hours agoTens of thousands protest in nationwide action against war in Gaza
-
General24 hours agoNRL live updates: Newcastle Knights vs Brisbane Broncos, Wests Tigers vs North Queensland Cowboys — blog, scores and stats
-
General19 hours agoThousands flood cities demanding action on Palestine